Closing Thoughts on the Treatment of MDD
Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.
Practical Considerations of Zuranolone Use in Treatment of MDD
Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.
Potential Adverse Effects of Zuranolone in MDD
Experts in psychiatry review adverse effects of zuranolone, a
γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.
GABAergic Modulating Treatment Considerations in MDD
Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.
Dosing Considerations of Zuranolone in MDD
Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.
GABAA Receptor Modulators for Treatment of MDD
Experts in psychiatry comment on the use of GABAA receptor modulators in the treatment of major depressive disorder (MDD), highlighting zuranolone.
New Treatment Options in MDD
Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC; review the mechanism of action of newer therapies in MDD treatment.
Communicating With Patients About MDD Treatment
Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC, discuss provider and patient communication about the time to onset of action of major depressive disorder (MDD) treatments and when the patient can expect to see a difference.
Defining Features of Rapid-Acting Therapies in MDD
Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).
Overview of Rapid-Acting Therapies in Major Depressive Disorder (MDD)
Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).
Key Takeaways for the Management of MDD
Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.
Unmet Needs in MDD Treatment Paradigm
Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.
Impact of Different MDD Classes of Treatment on Time to Response
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.
Current Challenges With MDD Treatment Options
Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.
Treatment Approaches for Episodic and Chronic MDD
Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.
Treatment Options for MDD
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.
Monitoring Recommendations for MDD
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.
Perception of MDD in the Healthcare Community
Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.
Depression and Comorbid Health Conditions
Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.
Impact of MDD Episode Duration and Recurrences
Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.
2 Commerce Drive Cranbury, NJ 08512